- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Metastatic hormone sensitive prostate cancer
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 900KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 751KB)
Abiraterone and methylprednisolone – July 2023
Abiraterone and methylprednisolone: Pack containing 120 tablets abiraterone (as acetate) 125 mg and 30 tablets methylprednisolone 4 mg; Yonsa Mpred®
Last updated
27 October 2023